drugset / Trial / NCT04449198

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

NCT04449198

Phase 0 Recruiting 24 enrolled Augusta University
RandomizedParallel-groupDouble-blindTreatment

Summary

The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.

Timeline

Start
2020-10-14
Primary completion
2027-01-01
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule 500 mg Oral